Clinical Trials on Thalassemia Major in Canada

Total 315 results

H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (Pyxis)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Canada, Slovakia
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, United States, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Mexico, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Latvia, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Poland, Serbia, Russian Federation, Germany, Canada, France
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Janssen Research & Development, LLC

Completed

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II)

Depressive Disorder, Major

United States, Belgium, Canada, Poland, France, Spain, Brazil, Lithuania, Czechia, Austria, Argentina, Turkey
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Spain, Argentina, Sweden, Germany, Canada, France, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Canada, Slovakia, Poland, Argentina, Bulgaria, Czechia, South Africa, United Kingdom, France, Brazil
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
Biotronik, Inc.

Terminated

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk (IMPACT)

Stroke | Atrial Fibrillation | Atrial Flutter | Major Bleeding | Embolism, Systemic Arterial

United States, Canada, United Kingdom, Denmark, Germany, Australia
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Recurrent Salivary Gland Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v7 | Malignant Salivary Gland Neoplasm

United States, Canada

Clinical Trials on Thalassemia Major in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations